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ABSTRACT
Metastasis is responsible for the majority of cancer related deaths. In breast cancer the
lungs and bones are the major sites for metastasis. Previous studies used the metastatic
aggressive MDA-MB-231 breast cancer line to isolate subclones that preferentially
invade the lungs (LM line) or bones (BoM line). While genes associated with the tissue
specific metastasis have been identified, it is unknown if metabolic adaptations contribute
to the growth of the LM and BoM lines in their respective organs. The goal of this study
was to test the hypothesis that the LM and BoM lines exhibit differences in glucose and
glutamine metabolism from their parent MDA-MB-231 breast cancer line. Such
differences would support the broader concept of metabolic plasticity as an important
component of cancer metastasis. We used 13C- metabolic flux analysis with 5-13C
glutamine as the labeled substrate. The rates of glucose uptake, glutamine uptake,
respiration, and lactate production were measured, together with 13C enrichment of
lactate. In parallel, the fraction of glutamine and glucose used for fatty acid synthesis was
assessed with the fatty acid synthase inhibitor C75. The measured fluxes were used to
determine fluxes through glycolysis, the pentose phosphate pathway, the tricarboxylic
acid (TCA) cycle, malic enzyme, and to fatty acids. The LM and BoM cells exhibited
significant metabolic differences from each other and the MDA231 parent line, this
supports our hypothesis and is consistent with such changes contributing to organspecific growth of these lines. Specifically, the LM and BoM lines have significantly
lower mitochondrial TCA cycle and respiratory chain activities. The LM cells have a
significantly higher malic enzyme flux, which together with restricted mitochondrial
activity, are proposed to reduce oxidative stress in the high oxygen environment of the
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lungs. The BoM cells that metastasize to bones consume significantly less glutamine and
have low mitochondrial activity suggesting they rely more heavily on aerobic glycolysis
for ATP synthesis in the oxygen-limited bone environment. These metabolic adaptations
suggest that organ specific metabolic difference may be a new way to potentially target
these cells through development of drugs.
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INTRODUCTION
A hallmark of cancer cells is their altered metabolism that was first demonstrated
as enhanced glycolytic production of lactate by Otto Warburg. Even when sufficient
oxygen is available to fully oxidize glycolytic-derived pyruvate in mitochondria, a greater
proportion of pyruvate is instead reduced to lactate; this phenomenon is known as the
Warburg effect, or aerobic glycolysis (6). It is thought to have a role in supporting rapid
cell proliferation by provision of ATP and/or glycolytic intermediates at a rate sufficient
to meet the biosynthetic demands (12). The metabolic demands placed on the anabolic
reactions partly depend on the types of concentrations of nutrients that can be imported
from the environment (11). For example, cancer cells have high demand for fatty acids to
synthesize phospholipids for new membranes. If exogenous fatty acids are limiting,
tumors must have the capacity to use glucose and/or glutamine for de novo synthesis. The
latter substrate is typically imported at a rate more than ten-fold greater than that of
untransformed cells and can be used to re-supply TCA cycle intermediates, and for the
synthesis of glutathione, ATP, NADPH and other metabolites important for proliferation
(6).
While metastatic cancers often exhibit higher rates of aerobic glycolysis than nonmalignant ones, it is unclear if the Warburg effect, or other characteristics of their
metabolic phenotype, varies as one or a few cells preferentially invade and grow in
different secondary tissues (10). Each secondary site represents a potentially distinct
microenvironment that may necessitate subtle adjustments in the tumor’s metabolic
phenotype for success (7). Besides distinct tissue microenvironments, metastasis to one
or more secondary sites depends on genetic heterogeneity within the primary tumor.
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Transcriptomics studies have been performed on the MDA-MB-231 breast cancer line
that commonly metastasizes to the bones and lungs (7). Highly selective bone or lung
metastasizing subclones (denoted BoM and LM lines, respectively) were developed from
injections of MDA-MB-231 cells into mice; lung and bone tumors were iteratively
isolated, expanded in culture then re-introduced in mice until the resulting lines
exclusively invaded either the lungs or bone when injected into immune deficient mice
(7, 8). The bone metastatic cells were not able to grow in the lungs demonstrating that
metastatic cells that grow well in one location may not grow well at another (8). In the
bone cell lines overexpression of interleukin-11(IL-11) and osteoponitin (OPN) with the
addition of chemokine receptor 4 (CXCR4) increases bone metastasis activity (10). In the
MDA-MB-231 cell line 10% of the cells contained CXCR4 which was in the bone
metastasis gene expression. When looking at the gene set for lung expression there was
only six genes the overlapped with the bone metastasis gene expression (7).
Overexpression of SPARC and ID1 significantly associated with metastasis to lung (10).
When examining the primary breast cancer tumors those expressing the lung metastasis
signature had higher activity while the bone metastasis signature did not (7). There are no
genes found that are overexpressed in LM or BoM that participate in metabolic pathways.
However, this does not eliminate the possibility of metabolic differences between these
cell lines.
We hypothesized that tissue-specific metastasis is associated with subtle
differences in metabolic reprogramming of glucose and glutamine metabolism to allow
continued proliferation and invasion in different organ microenvironments. Metabolic
differences in the cell lines could be because the microenvironment of the new organ to
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which they invade is different from where the tumor originally grew. Therefore, the aim
of the study was to determine whether the LM and BoM subclones have metabolic
variations relative to the original breast cancer line from which they are derived. In order
to test this hypothesis, we used a combination of pharmacological inhibitor studies and
13

C lactate labeling experiments with 5-13C glutamine.
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METHODS
A. Cell lines and culture
Metastatic breast cancer MDA-MB-231 cells (hereafter referred to as MDA231)
and the less aggressive T47D breast cancer cells were provided by Dr. Y.D. Zhou
(University of Mississippi, Department of Chemistry and Biochemistry). Sub-clones of
MDA231 cells that preferentially metastasize in lung (LM) and bone (BoM) were
generated by Massague’s lab (7,14). Both LM and BoM cells were obtained from Dr.
Kounosuke Watabe (Wake Forest University) and provided by Dr. Zhou. Cells were
routinely cultured using RPMI-1640 media supplemented with 10% fetal bovine serum
and 0.5% vol/vol penicillin-streptomycin in 10 cm polystyrene petri dishes at 37oC in a
humidified 5% CO2 incubator. Cells were maintained in culture for no more than 20
passages, and typically split twice a week. The day before each experiment,
approximately 1.0 x 106 cells were seeded in each well of 2-well Lab-Tek chambers.
Control wells received 2mL standard cell culture media while treatment wells were
incubated in glutamine-free RPMI-1640 media supplemented with 1.5 mM 5-13C
glutamine. Cells were incubated for 20-22 hours prior to experiments.
B. Materials (reagents)
Glutamate pyruvate transaminase, glucose-6-phosphate dehydrogenase (G6PDH),
lactate dehydrogenase, nicotinamide adenine dinucleotide phosphate (NADP),
nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), and 2
oxoglutarate were purchased from Calzyme (San Luis Obispo, CA). Hexokinase,
microbial glutamate dehydrogenase, 3-nitrophenylhydrazine, and N-(3dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) were purchased from Sigma (St.
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Louis, MO). Glutaminase was purchased from Megazyme (Chicago, IL). 5-13C glutamine
was purchased from Cambridge Isotopes (Tewksbury, MA). Cell culture media, fetal
bovine serum, and cell culture supplies were purchased from Fisher Scientific (Pittsburg,
PA). Buffers and other general reagents were purchased from Sigma.
C. Flux experiments
After overnight incubation in cell culture media  5-13C glutamine, cells were
rinsed then equilibrated 5 h 37oC in experimental buffer containing 137 mM NaCl, 5 mM
KCl, 20 mM TES, 1.3 mM CaCl2, 1.3 mM MgCl2, 1.2 mM Na2SO4, 0.4 mM KH2PO4,
0.2 mM NaHCO3, 5.5 mM glucose, 0.3 % fatty acid-free bovine serum albumin (BSA), 
1.5 mM 5-13C glutamine, pH 7.4. For some experiments, 40 M C75 (an inhibitor of fatty
acid synthase) was included in buffer containing 1.5 mM unlabeled glutamine to estimate
the proportion of glucose and glutamine used for fatty acid synthesis. The control buffer
contained no glutamine. Respiration rate of cells in each well was determined at 37oC in
2.15 mL fresh buffer using a custom-made setup with a Clark-type micro-oxygen
electrode (Micrelectrodes, Inc., Bedford MA) (Fig. 2). Data for each well was acquired
over 45-55 min. with a Powerlab A/D unit and Lab Chart software (AD Instruments).
Cells were rinsed once with buffer then serially incubated for 60 min, 120 min, and 60
min at 37oC with 350 L buffer. After each incubation period, buffer was collected in
microfuge tubes on ice, the cells were rinsed once, and then 350 L buffer added for the
next incubation period. Control wells without cells were incubated in parallel to correct
for evaporative volume changes over each incubation period. The samples were
centrifuged for 5 min. 4oC at 21,000 xg and supernatants stored at -20oC for metabolite
assays and mass spectrometry. The 60 min. incubations were used to assess average rates
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of glucose consumption and lactate production, while all three were used to assess
glutamine consumption. Cell pellets were visible for the MDA231 samples; these were
saved and assayed for protein content to correct for protein loss over each incubation
period. After the final incubation, wells were rinsed once with 1 ml phosphate buffered
saline (PBS) then solubilized for 15min at 37oC with 500 L 50 mM NaCl, 20 mM TES,
1% SDS, pH 7.3. The extracts were vortexed 2-3 min. then centrifuged 10 min. 21,000xg
10oC and the supernatants stored at -20oC for protein assay. The MDA231 cell pellets
were washed once with 200 L PBS, repelleted by centrifugation, then solubilized with
100 L SDS buffer and stored at -20oC.

Figure 1: This figure shows the set up for respiration measurement. Shown are the cells plated at the
bottom of chamber. A stir bar located in the media is being turned by a magnetic stirrer on the other side
of the cell chamber lid. In the container is an O2 electrode which measures the decreasing oxygen
concentration of the buffer.

D. Metabolite assays
D.1. Glucose Assay
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The samples and standards (5 l; run in triplicate) were added to 115 l buffer
containing 100 mM triethanolamine, 7 mM MgCl2, 2 mM ATP, 2 mM NADP, 1 U/ml
hexokinase, and 1 U/ml glucose-6-phosphate dehydrogenase, pH 7.3. Reduction of
NADP to NADPH occurs as glucose is oxidized over the 8-10 min incubation period.
The resulting samples were measured in a Shimadzu RF6000 spectrofluorophotometer
(ex = 341 nm, em = 464 nm).
D.2. Glutamine Assay
The samples and standards (6 l; run in duplicate) were added to 34 l buffer
containing 60 mM sodium acetate pH 4.9 with or without 1 U/ml glutaminase.
Glutaminase was used to convert glutamine to glutamate by cleaving the amino group to
release free ammonia. The samples were incubated in a water bath (37C) for 45 minutes.
After the incubation, the samples were added to another buffer which contained 300 mM
TRIS, 10 mM 2-oxoglutarate, 240 µM NADPH, and 2 u/mL of glutamate dehydrogenase.
The glutamate dehydrogenase catalyzed the reductive amination of 2-oxoglutarate to
glutamate using the free ammonia generated by the glutaminase reaction. This was
incubated for 1 hour and 30 minutes at room temperature in the dark because NADPH is
light sensitive. The samples were then measured in a Shimadzu RF6000
spectrofluorophotometer (ex = 341 nm and em = 464 nm). Our cells naturally produce
ammonia so to differentiate we run the standard without glutaminase and subtract the
NADPH fluorescence’s.
D.3. Lactate Assay
The samples and standards (5 l; run in triplicate) were added to 115 l buffer
containing 100 mM glycylglycine, 100 mM glutamate, 2 mM NAD, 1 U/ml lactate
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dehydrogenase, and 1 U/ml glutamate-pyruvate transaminase, pH 8.5. In this reaction (40
min), lactate is oxidized to pyruvate, NADH is produced, and pyruvate is removed by
transamination to facilitate conversion o f lactate to pyruvate. The samples were
measured in a Shimadzu RF6000 spectrofluorophotometer (ex = 341 nm, em = 464
nm).
D.4. Protein Assay
Quantitation of total protein in soluble cell extracts (duplicates, diluted 1:3 in
water) were determined by bicinchoninic acid (BCA) assay. Reactions (25 µl sample with
500 µl BCA reagent) were incubated for 30 min, 60oC, cooled, and quantitated at 562nm
using a Ultrospec 3100pro spectrophotometer (Amersham Biosciences). Bovine serum
albumin standards (0, 50, 100, 150, 200, 300, 400, and 500 ug/ml) dissolved in
solubilization buffer were run in parallel. Additionally, protein assays were run for the
MDA cell pellets to correct for protein lost over each incubation period. The MDA cells
have a much lower adherence to the plate than the three other lines. Due to this inequality
MDA cells were spun into pellets and assayed to measure the protein content as a form of
compensation to account for the cell loss during the experiment.
E. Lactate derivatization and mass spectrometry analysis of 13C lactate
UHPLC–MS/MS of derivatized lactate
The samples and lactate standards (14 l) were extracted with 2 volumes 100%
cold methanol and then incubated for 1 H , -20C, to precipitate buffer proteins. The
samples were then centrifuged at 21,000 xg, 2C for 10 min. The resulting supernatant was
then transferred to new tubes. Next the reagents 50 mM EDC (prepared fresh in 1.5%
pyridine, 98.5% ethanol, 21 l) and 140 mM NPH (prepared fresh in 50% ethanol, 21 l)
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were added to the tubes in that specific order to derivatize lactate with 3nitrophenylhydrazine. The reaction was incubated for 2 h, 37C, and then cooled on ice.
The samples (30 l) were then diluted in 970 l 80% methanol in mass spec vials for
analysis by liquid chromatography-triple quadrupole mass spectrometry. Both unlabeled
(M), 13C labeled (M1), and 66:1 M:M1 lactate standards were run to confirm the expected
masses (224 Da for M, 225 Da for M1) and verify separation of these isotopologues.
The derivatized samples were separated on a Waters ACQUITY I-Class UPLC™ system
including binary solvent manager, sample manager and column manager connected to a
Waters Xevo TQ-S triple quadrupole mass spectrometer (Waters Corp, Milford, MA,
USA). The separation was carried out on a Waters Acquity UPLC™ BEH C18 column
(50mm × 2.1mm i.d., 1.7 µm). The sample temperature and column temperature were
maintained at 10 C and 40 C, respectively. The mobile phase consisted of water
containing 0.1% formic acid (v/v) (A) and acetonitrile with 0.1% formic acid (B). The
analysis was performed using the following gradient elution at a flow rate of 0.50 mL/min:
0-2.5 min, 5% B to 18% B; 2.5-3 min, 18% B to 100% B. Each run was followed by a 2.5
min wash with 100% B and an equilibration period of 2.5 min with the initial conditions.
The

strong

and

weak

solutions

used

to

wash

the

auto

sampler

were

methanol/acetonitrile/isopropanol/water (25:25:25:25, v/v/v/v/v) and methanol/water
(70:30, v/v), respectively. The injection volume was 1 μl. The UHPLC effluent was
introduced into the Waters Xevo TQ-S mass spectrometer equipped with electrospray
ionization in negative ion mode (ESI-) for quantification of the analytes. Detection was
obtained by Multiple Reaction Monitoring (MRM) mode including two MRMs for
confirmation of the analytes. MRM transitions and related parameters are listed in Table 1.
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The quantification of analytes 224, 225, 226, and 227 (the expected masses for M, M1,
M2, and M3 lactate derivatized with nitrophenylhydrazine, respectively) was acquired with
transitions of deprotonated ion at m/z 224.04 → 152.06 for M, 225.04 → 152.06 for M1,
226.04 → 152.06 for M2, and 227.04 → 152.06 for M3 with dwell time of 20 msec at cone
voltage 44 V and collision energy 14 eV for each transition. The ESI–MS/MS parameters
were set as follows: capillary voltage, 1.20 kV; cone voltage, 44 V; source temperature,
150 C; desolvation temperature, 600 C; desolvation gas flow, 600 L/h, cone gas flow,
200 L/h. Nitrogen was used as desolvation and cone gas. Argon (99.99% purity) was
introduced as the collision gas into the collision cell at a flow rate of 0.15 mL/min. Data
acquisition was carried out by MassLynx 4.1 software and processed by TargetLynx
(Waters Corp., Milford, MA, USA).
Table 1 Optimized UHPL-MS/MS parameters for each analyte
[M-H]MRM transition
Cone
Collision
Analyte
(m/z)
(m/z)
votage (V) energy (eV)
M
224.04
224.04 -> 152.06
44
14
224.04 -> 137.11
22

Retention
time (min)
1.84

M1

225.04

225.04 -> 152.06
225.04 -> 137.11

44

14
22

1.84

M2

226.04

226.04 -> 152.06
226.04 -> 137.11

44

14
22

1.84

M3

227.04

227.04 -> 152.06
227.04 -> 137.11

44

14
22

1.84

F. Flux Calculations
For 13C glutamine experiments, measured fluxes include glucose uptake (J0),
lactate production (J4), mitochondrial respiration rate (JRR), and external glutamine
consumption (J10)., For C75 experiments, the fraction of glucose or glutamine used for
𝐽 𝐶75

fatty acid synthesis 1 − 𝐽 𝑐𝑛𝑡𝑙 , and the fraction of C75-senstive glucose diverted to lactate
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for ATP synthesis

0.5(𝐽4 𝑐𝑛𝑡𝑙− 𝐽4 𝐶75)
𝐽0 𝑐𝑛𝑡𝑙− 𝐽0 𝐶75

were measured. These data, along with 13C enrichment

in lactate, were the basis for assessing all intracellular fluxes using a Microsoft Excelbased computational model to optimize the following parameters: malic enzyme (J7)
contribution to total pyruvate produced, 𝐽

𝐽7

2𝑐 +𝐽7

= 𝑋 (where J2c = glycolytic flux from 3-

phosphoglycerate to pyruvate) , glutamate dehydrogenase (J11) contribution to total
alpha-ketoglutarate produced,
oxidized to -ketoglutarate,

𝐽11
𝐽11 +𝐽12𝑓

𝐽11
𝐽10

= 𝑌, and the fraction of exogenous glutamine

= 𝑍. The 14 fluxes not measured can be calculated from

the measured fluxes and model-optimized parameters as detailed below, provided that the
cells maintain a metabolic steady-state (i.e., the production and consumption of each
metabolite is equal). Mitochondrial respiration rate was not directly used to calculate
fluxes, but was important in providing constraints for calculation of fluxes through the
TCA cycle reactions.
𝐽

Given that the model finds the solution 𝐽11 = 𝑍 it follows that the rate of
10

glutamate oxidation to KG is calculated as:
𝐽11 = 𝐽10 ∙ 𝑍

(Eq.1)

The reductive carboxylation of KG to citrate (J12r) for fatty acid synthesis is calculated
from the C75-sensitive glutamine consumption:
𝐽 𝐶75

𝐽12𝑟 = 𝐽10 ∗ (1 − 𝐽 10𝑐𝑛𝑡𝑙)
10

Given the solution 𝐽

𝐽11

11 +𝐽12𝑓

(Eq. 2)

= 𝑌, the forward oxidation of citrate to KG is calculated by

solving for J12f:
𝐽12𝑓 =

𝐽11 (1−𝑌)
𝑌
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(Eq.3)

The glucose consumption for fatty acid synthesis was calculated by subtracting the C75sensitive glucose converted to lactate from the total C75-sensitive glucose uptake:
𝐽 𝐶75

𝐽 𝑐𝑛𝑡𝑙−𝐽 𝐶75

𝑔𝑙𝑐 𝑓𝑜𝑟 𝐹𝐴 = 0.36 ∗ [𝐽0 ∗ (1 − 𝐽 0𝑐𝑛𝑡𝑙) − 0.5 ∗ 𝐽0 ∗ (𝐽4𝑐𝑛𝑡𝑙−𝐽4𝐶75)]
0

0

(Eq. 4)

0

Equation 4 assumes that 11 glucose are required to synthesize each palmitate; four (36%)
are used as the carbons for the fatty acid and seven (64%) are used by the oxidative PPP
to generate the 14 NADPH required for palmitate synthesis. The rate of citrate used for
fatty acid synthesis is thus:
𝐽13 = 𝐽12𝑟 + 2 ∗ (𝑔𝑙𝑐 𝑓𝑜𝑟 𝐹𝐴)

(Eq. 5)

From the citrate balance, the total rate of pyruvate oxidation to citrate (J5) is:
𝐽5 = 𝐽12𝑓 + 𝐽13 − 𝐽12𝑟

(Eq. 6)

The malic enzyme flux (J7) is determined from the model-optimized ratio 𝐽

𝐽7

2𝑐 +𝐽7

= 𝑋 and

the relationship 𝐽2𝑐 + 𝐽7 = 𝐽4 + 𝐽5 . Substituting:
𝐽7 = 𝑋 ∗ (𝐽4 + 𝐽5 )

(Eq. 7)

From the pyruvate balance, lower glycolytic flux (J2c) is:
𝐽2𝑐 = 𝐽4 + 𝐽5 − 𝐽7

(Eq. 8)

3-phosphoglycerate flux to serine was assumed to be negligible, so flux from the triose
phosphates to 3-phosphoglycerate (J2b, middle glycolysis) is:
𝐽2𝑏 = 𝐽2𝑐

(Eq. 9)

Since the stoichiometry of NADH produced per 3-phosphoglycerate produced is 1:1, the
rate of glycolytic NADH production = J2b. Mitochondrial oxidation of glycolytic NADH
(J6, via the malate-aspartate shuttle) is thus the residual NADH not used to reduce
pyruvate to lactate:
𝐽6 = 𝐽2𝑏 − 𝐽4
12

(Eq. 10)

The glucose used for both the oxidative and non-oxidative pentose phosphate pathway for
NADPH and ribose-5-phosphate synthesis is the difference between the measured
glucose uptake and the rate of glycolytic production of 3-phosphoglycerate (J2b, in
glucose units):
𝐽𝑃𝑃𝑃= 𝐽0 − 0.5 ∗ 𝐽2𝑏

(Eq.11)

The rate of KG oxidation to succinate can be calculated from the KG mass balance:
𝐽14 = 𝐽11 + 𝐽12𝑓 − 𝐽12𝑟

(Eq.12)

Succinyl CoA consumption outside the TCA cycle was assumed to be negligible, so:
𝐽15 = 𝐽14

(Eq.13)

The rate of malate to OAA can be determined from the malate mass balance:
𝐽16 = 𝐽15 − 𝐽7

(Eq.14)

The citrate-derived oxaloacetate regenerated by fatty acid synthesis from glucose-derived
pyruvate was assumed to return to the TCA cycle, so that:
𝐽17 = 𝐽16 + 2 ∗ (𝑔𝑙𝑐 𝑓𝑜𝑟 𝐹𝐴)

13

(Eq.15)

RESULTS
A. Theory on predicting 13C lactate enrichment from 5-13C glutamine to assess TCA
cycle and malic enzyme activity
Glutamine supports the growth of many tumors as an anapleurotic and/or
bioenergetic substrate for the TCA cycle. The proportion of glutamine entering the TCA
cycle can be followed by 13C tracer analysis in one or more downstream metabolites. For
this study, we labeled cells with 5-13C glutamine and assessed downstream enrichment in
lactate exported to the experimental buffer. Enrichment in lactate was chosen as a means
to quantify fluxes through TCA cycle and malic enzyme reactions. Upon being taken up
by the cell, glutamine is deaminated to glutamate and then enters the TCA cycle by
oxidation to -ketoglutarate (KG), where the labeled carbon is retained at position 5 in
this metabolite (Fig. 2). Decarboxylation of carbon 1 occurs by KG dehydrogenase,
resulting in succinyl-CoA that retains the labeled carbon at position 4. Coenzyme A is
removed by succinate thiokinase, which yields the symmetrical product succinate; since
succinate dehydrogenase cannot distinguish between carbons 1 and 4, 50% of succinate is
13

C labeled at position 1 and 50% at position 4. The product fumarate is also

symmetrical, so the labeling pattern is retained as fumarate is converted to the nonsymmetrical product malate. From here there are two different routes that can be taken:
First, malic enzyme can decarboxylate carbon 4 of malate to generate pyruvate so only
50% of pyruvate generated in this way is expected to be labeled at carbon 1. Metabolism
of unlabeled glucose through glycolysis yields unlabeled that is assumed to mix with the
malic enzyme-derived pyruvate. Some of this pyruvate can be reduced to lactate to give
the same labeling pattern- single (M1) labeled lactate. Alternatively, some malate carbons
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are oxidized to oxaloacetate (OAA) such that the labeled carbons are retained in the same
order. Citrate synthase then catalyzes a condensation reaction with acetyl CoA from
pyruvate to form citrate, but since carbon 1 of pyruvate is lost upon conversion to
acetylCoA, citrate is labeled at either carbons 5, or 6,. Reductive carboxylation of 5-13C
KG to citrate can also yield citrate labeled at carbon 1. As citrate is oxidized to KG the
label at carbon 6 is removed. Therefore, as the second turn of the cycle begins, KG
labels occur at position 5 and position 1. However, when KG labeled at carbon 1 is
oxidized to succinyl-CoA carbon 1 is lost. Therefore, the labeling pattern of succinylCoA after the first turn of the cycle is not expected to change, so double (M2) and triple
(M3) 13C lactate labeling is not expected to occur.
The extent of M1 lactate enrichment partly depends on the contribution of glutamate
dehydrogenase (J11) to generating KG:
𝐽11

(Ratio 1)

𝐽11 +𝐽12𝑓

Lactate M1 enrichment also depends partly on the contribution of malic enzyme (J7) to
pyruvate production:
𝐽7

(Ratio 2)

𝐽2𝑏 +𝐽7

Therefore, a computational model was developed in which Eqs. 16 and 17 were
developed as optimized parameters that were varied by the Solver function in Excel to
reproduce the measured 13C lactate enrichment as close as possible.
The fraction of glutamine entering the TCA cycle
𝐽11
⁄𝐽
10

(Ratio 3)
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was also incorporated in the model because mitochondrial respiration rate imposes a
constraint on the reducing equivalents NADH and FADH2 generated by the TCA cycle as
glutamine is oxidized.

J7

Figure 2: 13C distribution in first and second turn of the TCA cycle with [5-13C] glutamine. The labeling
scheme begins with [5- 13C] glutamine as it enters the TCA cycle upon glutamate (Glu) oxidation (J11). The
colored circles indicate 13C labeled atoms and the open circles indicate 12C atoms. The carbons are
numbered starting with position 1 on the left. 13C glutamine enters the cycle labeled at position 5 as
glutamate is oxidized to -ketoglutarate (KG). As the glutamine carbons travel around the TCA cycle to
malate (Mal), which is then oxidized by malic enzyme (J7) to pyruvate (Pyr), 13C enrichment in lactate
(Lac) is expected only at carbon 1. Recycling of 13C as oxaloacetate (OAA) forms citrate (Cit) (J17) is not
expected to yield additional labeling of succinylCoA (SucC) or malate during subsequent turns of the cycle.

B. Glucose and glutamine for fatty acid synthesis
Rapidly dividing tumor cells have high demand for fatty acids to synthesize
phospholipids for new membranes. Exogenous fatty acids may be limiting, so many
tumors must use glucose and/or glutamine for de novo synthesis. To assess the proportion
of glucose and glutamine used to synthesize fatty acids and the overall rate of fatty acid
synthesis, tumor cells were treated with the fatty acid synthase (FAS) inhibitor C75.
When FAS is inhibited there should be less demand for glucose and/or glutamine;
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therefore, the rate of glucose and/or glutamine uptake from the media should decrease,
and the extent of the change (the C75-sensitive consumption) should provide an index of
the rate at which these substrates are used for fatty acid synthesis. Results from these
experiments were combined with those using 5-13C glutamine as detailed in Section F of
the Methods section.
Cells were preincubated in experimental buffer ± 40 µM C75 for 4 h and then
glucose and glutamine consumption were assessed over three sequential incubation
periods (1, 2, and 1 h). By 2-way ANOVA (cell line and C75 treatment as main effects),
there was a borderline significant main effect of C75 treatment on glucose (p=0.0496)
uptake (Fig. 3), suggesting that glucose may be used to synthesize fatty acids in these cell
lines. Glucose consumption was most affected in the T47D and MDA231 lines; the rates
with C75 were 81.6±4.7% (n=4; p=0.02 by one-tailed t-test) and 80.6±2.8% (n=3; p=0.02
by one-tailed t-test), respectively, of the controls (Fig. 3). In contrast, BoM and LM rates
were not significantly reduced (glucose consumption with C75 was 97.1±4.8%, n=4,
p=0.31 and 92.1±5.6%, n=3, p=0.15, of the respective BoM and LM controls). Lactate
production rate was also measured to determine if the decrease in glucose uptake rate can
be explained by a reduction in aerobic glycolysis; this could occur if inhibiting fatty acid
synthesis secondarily reduces ATP consumption, which in turn could affect glycolytic
rate. Consistent with this possibility, lactate production tended to be lower in the T47D,
MDA, and LM lines (Fig. 4), although there was no significant main effect of C75
(p=0.61 by 2-way ANOVA). Reduced aerobic glycolysis accounted for 33.7±13.8%,
23.9±12.8%, and 78.0±22.4% of C75-sensitive glucose uptake for LM, MDA, and T47D
lines, respectively. After accounting for the reduction in glucose converted to lactate for
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these 3 lines, and for the stoichiometry of palmitate synthesis from glucose (see Eq. 4),
the absolute and normalized rates of glucose diverted to fatty acids did not significantly
differ (p=0.09, p=0.20, respectively by 1-way ANOVA) between the cell lines (Fig. 6).
MDA cells notably had a higher glucose consumption rate (Fig. 6A) and a higher
proportion of glucose diverted to fatty acids (Fig. 6B), but the variability in these
measurements were too great to yield significant differences.
Inhibition of FAS had more pronounced effects on glutamine consumption
(p<0.0001 for main effect of C75 by 2-way ANOVA), suggesting that glutamine is the
preferred substrate for fatty acid synthesis. Glutamine consumption was significantly
reduced to similar extents in T47D (68.1±4.4% of controls, n=4, p=0.002), MDA
(68.4±8.2% of controls, n=3, p=0.026) and BoM (69.7±6.0% of controls, n=4, p=0.014)
lines, while LM cells were modestly affected (90.8±4.4% of controls, n=3, p=0.087). The
C75-sensitive glutamine consumption rates did not significantly differ between the lines
(p=0.12 by 1-way ANOVA; Fig. 7A); however, the lines significantly differed in the
proportion of glutamine diverted to fatty acids (p=0.01 by 1-way ANOVA). LM cells
diverted a significantly less (9.2±4.4%) glutamine to fatty acids compared to T47D
(31.9±4.4%), MDA (31.6±8.2%), and BoM (30.3±6.0%) cells (Fig. 7B).
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Figure 3 Effect of C75 on glucose uptake: Cells were incubated for 4 hours at 37C with or without 40 M
C75 and glucose uptake was determined over three sequential 1-2 hr incubations. Glucose concentrations
were measured by enzymatic assays as described in the methods. Data are mean  standard error of three
(LM, MDA231) or four (BoM, T47D) independent experiments. Asterisks * denote p< 0.05 compared to
corresponding control by t-test.

Figure 4 Effect of C75 on lactate production: Cells were incubated for 4 hours at 37C with or without 40
M C75. Lactate concentrations were measured by enzymatic assays as described in the methods. Data are
mean  standard error of three (LM, MDA231) or four (BoM, T47D) independent experiments. Asterisks *
denote p< 0.05 compared to corresponding control by t-test.
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Figure 5 Effects of C75 on glutamine consumption: Cells were incubated for 4 hours at 37C with or
without 40 M C75. Glutamine concentrations were measured by enzymatic assays as described in the
methods. Data are mean  standard error of three (LM, MDA231) or four (BoM, T47D) independent
experiments. Asterisks * denote p< 0.05 compared to corresponding control by t-test.

(A)

(B)

Figure 6 Absolute and fractional rates of C75-sensitive glucose diverted to fatty acids: (A) The absolute
rates of C75-senstive glucose to fatty acid were determined after subtracting the rate of C75-sensitive
glucose converted to lactate. One-way ANOVA indicated no significant cell line effect (p=0.09) (B) The
absolute rates in (A) were normalized to the rates of glucose uptake for the controls. One-way ANOVA
indicated no significant cell line effect (p=0.20).
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(A)

(B)

Figure 7 Absolute and fractional rates of C75-sensitive glutamine diverted to fatty acids: (A) The absolute
rates of C75-senstive glutamine to fatty acid were calculated as the difference in control and C75 rates.
One-way ANOVA indicated no significant cell line effect (p=0.12). (B) The absolute rates in (A) were
normalized to the rates of glutamine uptake for the controls. One-way ANOVA indicated a significant cell
line effect (p=0.01). Means sharing the same letter are not significantly different.

C. 13C lactate enrichment
Cells were pre-equilibrated for 20-22 h in cell culture media with 1.5 mM 5-13C
glutamine and then another 5 h in experimental buffer with 5mM glucose and 1.5 mM 513

C glutamine to allow isotopic steady-state labeling of intracellular metabolites; control

cells run in parallel were incubated with 5 mM glucose and no glutamine to assess
background 13C labeling. Compared to controls, all cell lines given 13C-glutamine had
significantly less unlabeled (M) lactate and significantly more 13C lactate (Fig. 8A, 8B).
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Importantly, virtually all 13C enrichment occurred as the M1 isotopologue (i.e., lactate
with a single 13C atom) with virtually none detected as M2 or M3 (Table 2). These results
are consistent with the predicted M1-only isotopologue labeling (Fig. 2) that is the basis
for the computational model to infer many of the fluxes within our metabolic map (Fig.
1). Furthermore, 13C enrichment in lactate in all four cell lines is consistent with use of
glutamine as an anaplerotic substrate to replace TCA cycle malate oxidized by malic
enzyme to produce NADPH (Fig. 1). It should also be noted that the fraction of M1
lactate did not increase for any cell line from the first to the second incubation period,
suggesting that isotopic steady-state labeling was reached.

(A)

Figure 8 M and M1 lactate content. Cell lines were equilibrated 26-27 h without or with 5-13C glutamine.
Fractional 13C lactate content was determined by mass spectrometry. (A) Unlabeled (M) lactate content.
(B) Single 13C labeled (M1) lactate content. Data are mean ± standard error of 4 experiments. Asterisks *
denote p< 0.05 compared to corresponding control cells this analysis was done by t-test.
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The specific 13C labeling enrichment was determined by subtracting background
enrichment (Table 2). LM cells M1 lactate content was 2 to 5-fold greater than the other
three lines; T47D cells exhibited intermediate M1 enrichment approximately 2 to 3-fold
higher than BoM and MDA cells. A computational model was used to optimize Ratios 1,
2, and 3 to reproduce as closely as possible the measured labeling. For this, the rates of
glucose consumption (J0), lactate production (J4), mitochondrial respiration (JRR), and
glutamine consumption (J10) (see A. Skubiz Honor’s thesis for details), together with
fractional glucose and glutamine used for fatty acid synthesis, were model inputs that set
the constraints for optimizing Ratios 1-3. The model closely reproduced lactate labeling
seen for T47D, BoM and MDA cells, but was less effective for the LM line (Table 2).
The limitation for the LM line was based on the low measured mitochondrial respiration
rate coupled with the high measured M1 lactate enrichment. The respiration rate set a low
limit for Ratio 2, and correspondingly this also limited Ratio 3. Nevertheless, the model
is a reasonably good fit to these cell lines for estimating glucose and glutamine
metabolism.
The model-optimized Ratios are shown in Table 3. The contribution of malic
enzyme to pyruvate production differed significantly between cell lines (p<0.0001) and
was highest for T47D and LM lines; this was expected given that these lines had the
highest enrichment of M1 lactate. The contribution of glutamate oxidation (J11) to KG
production differed significantly (p<0.0001); both MDA-derived metastatic variants
generated the majority of KG from glutamate (98% for LM and 65% for BoM),
suggesting low isocitrate dehydrogenase activity in these cells. The fraction of glutamine
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converted to KG also differed significantly between the lines (p=0.001); the less
aggressive T47D line shunted the highest fraction to KG (65%), suggesting the more
aggressive LM, MDA, and BoM lines (which shunted 35, 43, and 54%, respectively of
glutamine to the TCA cycle) used a higher proportion of glutamine for protein or small
peptide (e.g., glutathione) synthesis.
Table 2. Measured and Modeled 13Carbon Lactate Enrichment
Measured 13C Labeling
LM
BoM
MD
A
T47
D

Predicted 13C Labeling

M

M1

M2

M3

M

M1

0.9819±
0.0006c
0.9954±
0.0002b

0.0178±0.000
6c
0.0046±0.000
2b

0.0003±0

<0.0001±0

0.9864±0.0018

0

0

0.0092±0.0031

<0.0001±0

<0.0001±0

0.9954±0.0002

0.0136±0.00
18
0.0046±0.00
02

M2

M3

Model error

0

0

0.0002±0.0001

0.0066±
0.0006b

0.0033±0.000
6b

<0.0001±0.00
01

<0.0001±0

0.9966±0.0006

0.0034±0.00
06

0

0

0.0006±0.0001

0.9913±
0.0009a

0.0083±0.000
6a

0.0003±0.000
1

0.0002±0.0002

0.9916±0.0007

0.0084±0.00
07

0

0

0.0011±0.0004

Unlabeled (M), single- (M1), double- (M2), and triple- (M3) 13C labeled lactate produced by cell lines
metabolizing 5-13C glutamine was measured by mass spectrometry. Computational modeling was used to
reproduce the labeling pattern within the constraints of the measured fluxes J 0, J4, J11, and JRR (see Fig. 1).
Data are the mean  the standard error of four experiments per cell line. This table compares the measured
enrichment with the predicted enrichment from the computational model for 13C labeling. The model error
is the sum of the absolute value of the difference between M-M3 predicted and measured. Means that share
common letters within a column are not significantly different (significance level p<0.05).

Table 3. Model-optimized flux ratios
LM
BoM
𝐽7
⁄(𝐽 + 𝐽 )
0.0278±0.0040a 0.0132±0.0008b
2𝑏
7
𝐽11
⁄(𝐽 + 𝐽 ) 0.9821±0.0131d 0.6496±0.0302c
11
12𝑓
𝐽11
⁄𝐽
10

MDA

T47D

0.0127±0.0021b

0.0370±0.0028a

0.4988±0.0044b

0.4337±0.0092a

0.3559±0.0504c 0.5381±0.0093a,b 0.4350±0.0158b,c

0.6518±0.0387a

Table 3 Optimized flux ratios from the computational model. Data are means  the standard error of four
experiments. The means that share common letters within a row are not significantly different (significance
level p<0.05).
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D. Pathway Fluxes
From the model-optimized flux ratios and the measured fluxes (highlighted in red,
Table 4), the remaining fluxes for each cell line were determined as detailed in Section F
of the methods. Inferred fluxes will be highlighted here, as differences in the measured
fluxes have previously been detailed (see A. Skubiz thesis).
Measurement of lactate production alone does not necessarily report aerobic
glycolysis if there are glycolysis-independent sources of pyruvate (e.g., malic enzyme).
Since malic enzyme’s contribution to pyruvate (and by extension, lactate) differed
significantly between the cell lines (Table 3), removal of this contribution could impact
potential differences in aerobic glycolysis. However, in this case aerobic glycolysis
remained not significantly different between the three metastatic lines (MDA, LM, and
BoM rates: 31.3±2.1, 30.9±1.0, and 28.2±0.5 nmol lactate/min x mg) but significantly
higher than T47D cells (9.47±0.43 nmol lactate/min x mg). Lactate production alone does
not assess total glycolysis (glucose to pyruvate) since some glycolytic-derived pyruvate is
used for other purposes (e.g., mitochondria oxidation; fatty acid synthesis). Total
glycolysis (J2c and J2b) was determined from measurements of mitochondrial respiration
rate, lactate production rate, C75-sensitive glucose and glutamine consumption, and
glutamine used to support malic enzyme flux. While aerobic glycolysis did not differ
between MDA, BoM, and LM cells, total glycolytic flux of MDA cells was significantly
greater than BoM cells (p=0.02), while LM flux did not differ from either of these lines.
The MDA-BoM difference was a consequence of a significantly higher rate of
mitochondrial pyruvate uptake (J5) by MDA cells. Notably, mitochondrial pyruvate
uptake for LM and BoM cells was not different, but substantially diverged from their
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parent MDA231 cells (Table 4). This trend was also apparent with mitochondrial uptake
and oxidation of glycolytic-derived NADH (J6), and with TCA cycle reaction fluxes (J12f,
J14, J15, J16, and J17). These results further suggest significant changes in mitochondrial
function between the MDA231 lines and the BoM and LM lines. It is also worth
mentioning that the LM TCA cycle did not operate as a continuous cycle as with the
other cell lines in that virtually all pyruvate entering was shunted to fatty acid synthesis,
so the forward cycle was interrupted from citrate to KG. However, from KG to malate
the forward cycle was supported by glutamine influx but was again interrupted with
virtually no malate being oxidized to oxaloacetate (Table 4); oxaloacetate for citrate
synthesis was effectively ‘recycled’ from that released from citrate used during fatty acid
synthesis.
Glucose uptake that was not used for aerobic glycolysis, mitochondrial oxidation,
or fatty acid synthesis was assumed to be shunted into the oxidative and non-oxidative
pentose phosphate pathways. These experiments did not allow differentiation between
these two pathways and so were grouped together as a single pentose phosphate pathway
(PPP) flux (Table 4). The MDA and LM PPP fluxes were not different, but both
exhibited significantly, or borderline significantly (for LM vs. T47D, p=0.0502) greater
fluxes compared to T47D cells. Glucose used by the PPP in the BoM line was no
different from the T47D cells, which was unexpected given that demand for de novo
nucleotide synthesis is predicted to be higher in the more rapidly proliferating BoM line.
When normalized to total glucose uptake rate, BoM glucose shunted to the PPP remained
significantly lower than the other three cell lines, which were not different from one
another (percent glucose used by PPP for T47D, MDA, LM, and BoM lines was
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31.2±3.7%, 23.5±3.0%, 22.5±2.3%, and 12.5±3.1%, respectively); it was surprising that
the least metastatic, slow growing T47D line tended toward using the highest proportion
of glucose for the PPP.
Finally, malic enzyme activity was approximately two-fold higher in LM cells
compared to the other three lines (Table 4). Malic enzyme account for approximately
98% of malate consumption in these cells; by comparison, malic enzyme consumed
approximately 21%, 45%, 28% of malate in MDA, BoM, and T47D cells, respectively.

Table 4. Measured and Modeled Fluxes
T47D
J0 (nmol glc/min x mg)
7.79±0.26a
J1+J3 (nmol HxP/min x
mg)
2.43±0.33a,b
J2a
nd
J2b (nmol TrP/min x mg)
10.7±0.5a
J2c (nmol 3PG/min x mg)
10.7±0.5a
J4 (nmol lac/min x mg)
9.83±0.43a
J5 (nmol pyr/min x mg)
1.28±0.03a
J6 (nmol NADH/min x
mg)
0.87±0.03a
J7 (nmol mal/min x mg)
0.41±0.03a
J8
nd
J9
nd
J10 (nmol gln/min x mg)
1.24±0.12a
J11 (nmol glu/min x mg)
0.81±0.05a
J12f (nmol cit/min x mg)
1.05±0.03a
J12r (nmol aKG/min x
mg)
0.39±0.04a,c
J13 (nmol cit/min x mg)
0.62±0.04a
J14 (nmol aKG/min x
mg)
1.46±0.05a
J15 (nmol suc/min x mg)
1.46±0.05a
J16 (nmol mal/min x mg)
1.05±0.03a
J17 (nmol oaa/min x mg)
1.28±0.03a

MDA231
23.1±1.0b

BoM
16.6±0.53c

LM
20.5±0.1d

5.44±0.63c
nd
35.4±2.2b
35.4±2.2b
31.7±2.0b
4.15±0.13b

2.07±0.59a
nd
29.1±0.4c
29.1±0.4c
28.6±0.5b
0.83±0.07c

4.59±0.46b,c
nd
31.7±1.1 b,c
31.7±1.0b,c
31.8±1.1b
0.80±0.02c

3.69±0.16b
0.46±0.04a
nd
nd
3.82±0.18b
1.66±0.04b
1.67±0.04b

0.44±0.05c
0.39±0.02a
nd
nd
1.66±0.06a
0.89±0.03a,c
0.48±0.07c

0.05±0.05d
0.91±0.15b
nd
nd
3.44±0.27b
1.22±0.14c
0.02±0.02d

1.21±0.06b
3.68±0.15b

0.50±0.02a
0.85±0.03a,c

0.32±0.03c
1.09±0.02c

2.13±0.05b
2.13±0.05b
1.67±0.04b
4.15±0.13b

0.87±0.09c
0.87±0.09c
0.48±0.07c
0.83±0.07c

0.93±0.17c
0.93±0.17c
0.02±0.02d
0.80±0.02c

All fluxes are expressed as nmol of substrate consumed per minute per mg cell protein. Data are mean 
standard error of 4) experiments for each cell line. The red boxes are the measured fluxes. The remaining
fluxes were inferred from the computational model optimizing three flux ratios to reproduce the measured
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13

C enrichment in lactate. Glucose used for the oxidative and non-oxidative pentose phosphate pathways
(J1 and J3, respectively could not be resolved and so were combined to report overall pentose phosphate
flux. Means sharing common superscripts do not significantly differ the significance level P<0.05. nd: not
determined. Abbreviations: glc: glucose; HxP: hexose phosphates, including glucose-6-phosphate and
fructose-6-phosphate; TrP: triose phosphates, including glyceraldehyde-3-phosphate and
dihydroxyacetone phosphate; 3PG: 3-phosphoglycerate; lac: lactate; pyr: pyruvate; mal: malate; gln:
glutamine; glu: glutamate; cit: citrate; aKG: -ketoglutarate; suc: succinyl-CoA; oaa: oxaloacetate.
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DISCUSSION
The overall goal of this study was to determine if metastatic sub-clones that
preferentially invade and grow in lung or bone tissue exhibit metabolic differences from
the parent MDA231 breast cancer line. Such metabolic plasticity may be important for
tumor growth in different tissue microenvironments, and may guide development of
tumor-specific, metabolic-targeted therapies. The major glucose-consuming pathways
were quantified with a moderate degree of resolution using the principles of 13C
metabolic flux analysis with 5-13C glutamine and unlabeled glucose as substrates. The
major finding from this study is that LM and BoM cells exhibit significant metabolic
differences from each other and from the MDA231 parent line. Specifically,
mitochondrial oxidation of both pyruvate and glutamine is lower in both the LM and
BoM lines; consistent with this, less glycolytic NADH is shuttled into mitochondria for
oxidation and a greater fraction of glucose is converted to lactate in the BoM and LM
lines. Other notable differences include lower PPP flux in BoM cells, lower de novo fatty
acid synthesis flux in both BoM and LM cells, and higher malic enzyme flux in LM cells.
Glucose and glutamine are critical nutrients for cancer cell growth. Both of these
nutrients can be metabolized to substrates that are oxidized in the TCA cycle to produce
ATP. Glucose is transformed to pyruvate through glycolysis which then enters the TCA
cycle or is reduced to lactate (4). Pyruvate entering the TCA may be incompletely
oxidized and instead used for fatty acid synthesis as acetylCoA derived from the TCA
cycle metabolite citrate. In addition to pyruvate, glycolysis generates other metabolites
that are substrates for anabolic pathways. Glucose-6-phosphate is oxidized through the
oxidative pentose phosphate pathway to produce ribose phosphates for synthesis of
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nucleic acids (2) and NADPH for a number of biosynthetic pathways and for protection
against reactive oxygen species (ROS). Fructose-6-phosphate and glyceraldehyde-3phosphate are substrates for the non-oxidative pentose phosphate pathway (running in
reverse) that also produces ribose phosphates. Serine and glycine are synthesized from 3phosphoglycerate; serine can be further metabolized in the folate cycle to support
nucleotide synthesis. The majority of glutamine not used for protein synthesis is
deaminated within mitochondria to glutamate by glutaminase (GLS). Glutamate is
oxidized by glutamate dehydrogenase to the TCA cycle metabolite KG. The
deamination of glutamine to glutamate generates nitrogen (as ammonia) which is used for
nucleotide biosynthesis and nonessential amino acids (1). Production of KG from
glutamine is important to replace TCA cycle metabolites removed from the cycle by
other reactions. For example, malic enzyme oxidizes malate to pyruvate which can either
re-enter the TCA cycle or be reduced to lactate. When malate is oxidized in this way,
NADPH is produced which contributes to maintaining the cellular redox state for
biosynthetic reactions and protection against ROS. (1). Glutamate is also a substrate for
glutathione synthesis; this tripeptide is important for protection against ROS as well as
for biosynthetic reactions. Cancer cells have a higher flux of substrates through many
anabolic pathways to produce nucleotides, fatty acids and non-essential amino acids
necessary for their rapid proliferation. In this way, glucose and glutamine consumption
rates are higher in cancer cells. However, different types of cancer cells may exhibit
differences in fluxes through specific pathways as a result of differences in either their
capacity to transport exogenous nutrients from the extracellular fluid (ECF), their
expression of genes coding for different pathways, or the composition of the
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ECF/availability of nutrients given the tissue in which the cells proliferate. From this
perspective, metastatic cancers that preferentially grow in different organs may do so
partly because of metabolic differences.
As expected, the aggressive metastatic MDA231 cell line exhibited significantly
greater total glycolytic (glucose to pyruvate) and aerobic glycolytic (glucose to lactate)
flux compared to the less metastatic T47D cell line (Fig 9). The importance of increased
aerobic glycolysis is likely for generating glycolytic intermediates at a rate sufficient to
support anabolic processes (5), but may also be important for adequate supply of ATP.
These results are similar to another study showing 2-3 fold higher glucose consumption
and lactate production for MDA-MBA-231 cells (6). The high aerobic glycolysis of more
metastatic cells is often associated with lower mitochondrial activity; this has often been
interpreted that metastatic cells have dysfunctional mitochondria deficient in pyruvate
oxidation and ATP synthesis. Surprisingly, we found that MDA231 cells had
significantly higher respiration rate and TCA cycle fluxes compared to T47D cells.
Pyruvate flux to citrate to meet greater demand for fatty acid synthesis was a notable
contributor to the cycle. While the proportion of oxygen used to synthesize ATP was not
assessed, greater TCA cycle activity implies that MDA mitochondria are functional and
important contributors to cellular ATP synthesis. The higher rates of aerobic glycolysis
and mitochondrial respiration and TCA cycle activity imply that MDA cells have a
significantly greater ATP demand. While some of this may be due to greater activity of
ATP-dependent anabolic pathways, the differences in cell morphology may also
contribute. MDA231 cells are more elongated, with many having neurite-like extensions;
they also do not adhere together, while T47D cells are more rounded and form tight
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clusters. These observations suggest MDA231 cells have a greater plasma membrane
surface area:cell volume ratio that would promote greater plasma membrane ion cycling
and correspondingly a greater demand for ATP to maintain appropriate ion gradients.
Further experiments are required to assess how differences in cell morphology might
contribute to ATP demand and whether the efficiency of mitochondrial ATP synthesis
differs.
Oxidative/non-oxidative PPP flux was 2.2-fold greater in MDA cells; these cells
thus have higher NADPH and pentose phosphate demand for redox homeostasis and
nucleotide synthesis than T47D cells (2). Experiments are in progress to resolve the
proportion of glucose through the oxidative and non-oxidative pathways It was somewhat
surprising that the proportion of total glucose used by the PPP tended to be higher for
T47D than MDA cells, (31.2±3.7% vs. 23.5±3.0% of total glucose, respectively; p=0.36)
given the more malignant nature of the latter cell line. Some of this difference could be
attributed to MDA cells tending to use a greater proportion of glucose for fatty acid
synthesis (5.1±1.5% vs. 1.4±1.1%, respectively; p=0.32). Since oxidative PPP flux is
subject to strong feedback inhibition by NADPH, MDA231 cells may have less demand
for this cofactor. This would most likely derive from less consumption for antioxidant
defenses given the greater demand for fatty acid synthesis and potentially other
biosynthetic reactions. Glutathione and thioredoxin reductases are major NADPH
consumers to protect against ROS; MDA cells could either produce less ROS and so
require less NADPH, or have deficits in reductase activities.
Glutamine consumption was 3-fold higher in the MDA cells. One reason for this
was to support the significantly higher rate of fatty acid synthesis by reductive
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carboxylation of KG. The flux of both glucose and glutamine to fatty acid is sufficiently
high to indicate MDA cells could be vulnerable by therapeutically targeting this pathway.
However, a significantly greater proportion of glutamine used by T47D cells entered the
TCA cycle (Table 3). This suggests MDA cells preferentially use glutamine for processes
other than resupplying TCA cycle metabolites removed by anabolic reactions; such
processes would include glutamine/glutamate use for protein and glutathione synthesis.
Higher MDA demand for protein synthesis is expected based on the greater proliferation
rate of this cell line. Interestingly, de novo glutathione synthesis is predicted to be
relatively high if MDA cells are deficient in glutathione reductase. Experiments are
ongoing to assess the proportion of glutamine used for glutathione synthesis.

Figure 9: Comparison of MDA231 to T47D fluxes. Numbers are the ratios of MDA to T47D fluxes (Table
3) for each group of reactions. Green and red arrows denote MDA fluxes significantly greater than or less
than, respectively, the corresponding T47D fluxes. Blue arrows denote fluxes that were not significantly
different.

The malignant LM and BoM subclones exhibit significant metabolic differences
from their parent MDA231 line, which supports our hypothesis and is consistent with
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such changes contributing to organ-specific growth of these lines. The most notable
difference is that both lines have significantly lower mitochondrial TCA cycle and
respiratory chain activities (Figs 10 and 11).

Figure 10: Comparison of LM to MDA231 fluxes. Numbers are the ratios of LM to MDA231 fluxes (Table
3) for each group of reactions. Green and red arrows denote MDA fluxes significantly greater than or less
than, respectively, the corresponding T47D fluxes. Blue arrows denote fluxes that were not significantly
different.

Such changes may be particularly important for LM cells that preferentially metastasize
to the lungs, which is a unique organ in two ways- they receive 100% of cardiac output
and thus have the highest blood flow per mass tissue of any organ (Table 5) and have the
highest dissolved oxygen content (PO2 approximately 100 mmHg vs. systemic organs
where PO2 is approximately 20 mmHg) due to their close proximity to atmospheric air.
Mitochondria are primary producers of ROS through electron leak to oxygen from the
respiratory chain to produce superoxide. The rate of superoxide production partly
depends on the concentration of dissolved oxygen; cells in the lungs are thus more
susceptible to ROS production, and hence to oxidative stress. However, ROS production
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also depends on the redox state of the respiratory chain carriers and the TCA cycle
dehydrogenase prosthetic groups (e.g., flavin, thiamine pyrophosphate, and iron-sulfur
groups); the greater proportion of reduced prosthetic groups, the more likely electron leak
to oxygen would occur. These groups can be maintained in a more oxidized state if
substrate supply to mitochondria is restricted.

Figure 11: Comparison of BoM to MDA231 fluxes. Numbers are the ratios of BoM to MDA231 fluxes
(Table 3) for each group of reactions. Green and red arrows denote MDA fluxes significantly greater than
or less than, respectively, the corresponding T47D fluxes. Blue arrows denote fluxes that were not
significantly different.

Consistent with this possibility, LM cells oxidize pyruvate at only 20% the rate of MDA
cells; further, isocitrate dehydrogenase activity is virtually absent, which would not only
eliminate ROS production by this enzyme, but also by KG dehydrogenase due to further
limiting supply of this substrate. In another experiment, proteomic comparison of MDAMB-438 cells and a sub-clone that metastasizes to lung, it was found that peroxiredoxin
overexpression was important for lung metastasis (13). Peroxiredoxin (PRDX2) protects
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against oxidative stress by reducing hydrogen peroxide to water (13). By comparison,
PRDX2 expression in bone tissue was decreased (13); this is consistent with growth in
the lungs requiring adjustments that limit ROS levels. LM cells also shunt the lowest
proportion of glutamine to KG (Table 3); this may also contribute to restricting TCA
cycle substrate availability in addition to making more glutamate available for
glutathione synthesis. The blunted fatty acid synthesis is likely a secondary consequence
of limiting TCA cycle substrate availability; presumably LM cells would have to
compensate for this by enhanced reliance on exogenous fatty acids. Increased availability
of NADPH by significantly enhanced malic enzyme flux would also reduce oxidative
stress. Taken together, these findings are consistent with metabolic adjustments in LM
cells to minimize ROS production and oxidative stress in the high oxygen environment of
the lungs.
In contrast to the lungs, bone tissue has the lowest blood flow (Table 5). Since
blood flow determines the rate at which oxygen, glucose, and glutamine are delivered,
BoM metabolism may reflect adaptation to this nutrient-limited environment. These cells
use a significantly smaller proportion of glucose for the PPP (12.2±3.1%) than the other
three lines and have the lowest PPP flux; this is consistent with lower demand for
NADPH, possibly due to limited oxygen availability and hence less ROS production.
However, these cells proliferate at a rate greater than MDA cells and close to that of LM
cells in vitro so it is difficult to understand how the low PPP flux could provide pentose
phosphates at a rate adequate to meet the demand for nucleotide synthesis. Low
mitochondrial respiratory chain and TCA cycle activities could reflect the limited oxygen
supply to bone. They also consume significantly less glutamine than the MDA and LM
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lines, which could be a consequence of limited mitochondrial substrate oxidation
capacity. The finding that BoM cells have the highest lactate:glucose ratio further
suggests they rely more heavily on glycolytic ATP production for their energy. In this
respect, BoM cells may be particularly susceptible to therapies that interfere with
glycolysis.

Table 5. Mass adjusted comparison of tissue blood flow rates.
Tissue
Blood flow (ml/min x 100 g
tissue)
Bone
1.5-2.0
Dermis (skin)
4-10
Skeletal muscle
5-10
Intestine
30
Brain
57
Heart
70
Kidney
350
Lung
300-500
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CONCLUSIONS
In conclusion, LM and BoM cells exhibit significant metabolic differences from each
other and from the MDA231 parent line. This supports our hypothesis of metabolic
reprogramming for organ specific growth. TCA cycle and mitochondrial respiratory
chain activities are lower for the LM and BoM lines, while both convert a greater fraction
of glucose to lactate. Malic enzyme flux was twice as great in LM cells. It appears that
LM metabolism has adjusted to minimize ROS levels in the high oxygen content of the
lungs by limiting substrate availability to mitochondria while enhancing malic enzyme
production of NADPH. These cells may be vulnerable to inhibition of antioxidant
defense mechanisms and/or glycolysis. The BoM cells shunted the smallest fraction of
glucose through the PPP and the largest fraction to lactate, which could be an adaptation
to the low oxygen availability in bone because of the low blood flow to this tissue. These
results suggest that LM cells may be vulnerable to inhibition of antioxidant defense
enzymes while BoM cells may be more vulnerable to glycolytic inhibition. MDA231
cells were unique in having both high glycolytic and mitochondrial activities, as well as
3-5-fold higher de novo fatty acid synthesis. These cells may be vulnerable to targeted
inhibition of fatty acid synthesis. Taken together, these metabolic differences highlight
pathways that could help treat tissue-specific metastatic breast cancers.
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